Consequences of counterfeit pharmaceutical product sales
Recently, both the FDA and EMA have raised concerns about counterfeit drug products, including GLP-1s used for weight loss and diabetes, being marketed in the...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Taylor Rubinato is a principal in the Life Sciences Practice of CRA.
She has worked on projects related to antitrust, patent infringement, reasonable royalty determination, agreement disputes, reverse payment, and commercial success in the US and Canada. Her responsibilities include supporting expert witnesses on litigation cases, conducting data analyses, and project management.
